Compare Summit Therapeutics Inc (SMMT) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs ProShares UltraPro QQQ ETF — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while ProShares UltraPro QQQ ETF trades at $70.9. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | TQQQ | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.32 | $87.22 |
52-Week Low | $13.05 | $37.89 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
TQQQ trades at $67.65, up 0.18% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's structure amplifies daily Nasdaq-100 returns, yet financial ratios are unavailable as it's a leveraged fund tracking an index. Recent news highlights volatility risks, with articles warning of amplified losses during market downturns despite historical gains in bull markets.
Outlook remains cautious due to leverage decay and bearish technicals; opportunities exist for tactical traders during rebounds, but risks include heightened volatility and structural costs. Long-term holders face potential erosion from daily rebalancing, especially in sideways or declining markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
